Summit Therapeutics (SMMT) Gets a Hold Rating from H.C. Wainwright

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Summit Therapeutics (SMMTResearch Report). The company’s shares closed last Tuesday at $6.48.

According to, Arce is a 5-star analyst with an average return of 18.5% and a 41.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Summit Therapeutics.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.30 and a one-year low of $3.14. Currently, Summit Therapeutics has an average volume of 185.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.